Mealey's (April 13, 2022, 1:56 PM EDT) -- SAN FRANCISCO — A biotechnology company CEO’s sale of 2 million stock options awarded to him by the company’s board of directors less than six months earlier did not violate federal securities law because the senior executive’s transaction was exempted from the statute’s holding requirement, a Ninth Circuit U.S. Court of Appeals panel ruled April 8 in affirming....